Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients
-
Published:2017-02
Issue:
Volume:72
Page:54-61
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Carton E.,
Noe G.ORCID,
Huillard O.ORCID,
Golmard L.,
Giroux J.,
Cessot A.,
Saidu N.E.B.ORCID,
Peyromaure M.,
Zerbib M.,
Narjoz C.,
Guibourdenche J.,
Thomas A.,
Vidal M.,
Goldwasser F.,
Blanchet B.,
Alexandre J.
Subject
Cancer Research,Oncology
Reference25 articles.
1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015
2. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer;Mitsiades;Cancer Res,2013
3. CYP17A1 inhibitors in castration-resistant prostate cancer;Gomez;Steroids,2015
4. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men;Acharya;Cancer Chemother Pharmacol,2012
5. A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects;Acharya;Xenobiotica,2013
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献